Although substantial evidence suggests that treatment of dyslipidemia with statins reduces mortality and morbidity that are associated with cardiovascular disease, only a few studies have examined the efficacy of statins on inflammatory and fibrinolytic status in patients with chronic kidney disease (CKD). A 6-mo, prospective, randomized study was designed to assess the efficacy of atorvastatin in reducing circulating inflammatory and fibrinolytic parameters in patients with CKD. Sixty-six patients with CKD (stages 2, 3, and 4) and LDL cholesterol levels >100 mg/dl were randomly assigned (2:1) to receive 20 mg/d atorvastatin (n ‫؍‬ 44) or nonatorvastatin therapy (n ‫؍‬ 22). Lipid profile, renal function, fibrinolytic balance (tissue plasminogen activator [t-PA] and plasminogen activator inhibitor-1), and inflammatory markers (C-reactive protein [CRP], IL-1␤, IL-6, and TNF-␣) were measured before and 6 mo after atorvastatin was added to the treatment. Twenty-five age-matched individuals with normal renal function (estimated GFR >90 ml/min) were used as healthy control subjects. Patients with CKD had higher CRP, IL-1␤, TNF-␣, and IL-6 levels than age-matched population with normal renal function. t-PA concentration was higher in patients with CKD (P ‫؍‬ 0.000). Plasminogen activator inhibitor-1 values were comparable in all patients. Total cholesterol and LDL cholesterol were significantly reduced only in patients who received atorvastatin. In addition to the hypolipidemic effect, atorvastatin treatment significantly reduced inflammatory parameters: CRP (median 4.1 to 2.9; P ‫؍‬ 0.015), TNF-␣ (6.0 ؎ 2.7 to 4.7 ؎ 2.4; P ‫؍‬ 0.046), and IL-1␤ levels (1.9 ؎ 0.7 to 1.2 ؎ 0.7; P ‫؍‬ 0.001). These parameters remained unchanged in patients who were not treated with atorvastatin. Fibrinolytic parameters were not modified by atorvastatin treatment. Patients with CKD showed higher levels of inflammatory parameters and t-PA levels than age-matched healthy control subjects. Atorvastatin treatment, in addition to its beneficial effect on cholesterol levels, improved the inflammatory state of these patients without modifying fibrinolytic balance. than the general population (1,2). They have an altered plasma lipid profile that is characterized by increased levels of triglycerides, decreased levels of HDL cholesterol, and no consistent change in LDL cholesterol (3). Furthermore, dyslipidemia is considered a major cause of CVD in patients with CKD, and management of dyslipidemia plays an important role in the therapy of these patients (4,5).
P atients with chronic kidney disease (CKD) have a markedly higher prevalence of cardiovascular disease (CVD) than the general population (1, 2) . They have an altered plasma lipid profile that is characterized by increased levels of triglycerides, decreased levels of HDL cholesterol, and no consistent change in LDL cholesterol (3) . Furthermore, dyslipidemia is considered a major cause of CVD in patients with CKD, and management of dyslipidemia plays an important role in the therapy of these patients (4, 5) .
It has been established that the benefits of hepatic hydroxymethyl glutaryl-CoA reductase inhibitors, or statins, in cardiovascular disease can be explained not only by their lipid-lowering potential but also by non-lipid-related mechanisms, the so-called "pleiotropic effects." Some of these beneficial effects are related to the anti-inflammatory and fibrinolytic properties of statins, which may contribute to this positive effect of statins on the incidence of cardiovascular events (6, 7) .
It was published recently (8, 9 ) that reducing the inflammatory component of cardiovascular disease through the use of statin therapy improves the clinical outcome independent of the reduction in serum cholesterol levels. Although substantial evidence suggests that treatment of dyslipidemia with a statin reduces morbidity and mortality that are associated with CVD (10, 11) , only a few studies have examined the efficacy of statins on dyslipidemia and the inflammatory (12) and fibrinolytic system in patients with CKD, and most of these studies were performed in patients who had ESRD and were on dialysis but not in nondialyzed patients. The present prospective study was designed to evaluate the inflammatory and fibrinolytic status in patients with CKD in comparison with an age-matched group with normal renal function and to assess the effect of atorvastatin on dyslipidemia and inflammatory and fibrinolytic parameters in this population of patients with CKD.
Materials and Methods
Sixty-six patients with CKD (stages 2 to 4) from the Renal Clinic were enrolled. Inclusion criteria were CKD with an estimated GFR Ͻ90 ml/min and Ն15 ml/min. Exclusion criteria were levels of fasting serum LDL cholesterol of Ͻ100 mg/dl and Ͼ200 mg/dl; the existence of liver, cardiovascular, infectious, or systemic disease unrelated to ESRD; and the history of vascular intervention, congestive heart failure, or myocardial infarction within the 3 mo preceding the period of enrollment. No patient took lipid-lowering medication during the 4-wk period before the study.
All patients who met the eligibility criteria (n ϭ 66) were randomly (2:1) assigned to two groups. Group A included 44 patients who tool atorvastatin (20 mg/d for 6 mo), and group B included 22 patients who did not take lipid-lowering drugs. Patients who were already taking other drugs kept their pharmacologic schedule constant during the study. Fifty-five (83%) of 66 patients were receiving renin-angiotensin system blockers, and their dosages were not changed during atorvastatin therapy.
In addition, to analyze baseline inflammatory and fibrinolytic system in patients with CKD, we compared the basal data of patients who had CKD with an age-matched control subjects (n ϭ 25) who had no renal disease (no history of renal impairment and estimated GFR Ն90 ml/min). Venous blood samples were obtained before and after 6 mo of atorvastatin treatment and stored frozen at Ϫ80°C.
Serum creatinine, total cholesterol, HDL cholesterol, LDL cholesterol, and serum triglyceride levels were determined by means of standard enzymatic methods. Serum fibrinogen was determined by a standard method. GFR was estimated by the Cockroft-Gault formula. Highsensitivity C-reactive protein (CRP) plasma levels were measured with a latex-based turbidimetric immunoassay on a Hitachi analyzer (Sigma Chemical Co., St. Louis, Mo). IL-6, IL-1␤, and TNF-␣ were measured using quantitative sandwich enzyme immunoassay. A human specific mAb for IL-1␤, IL-6, or TNF-␣ was precoated into microplates (R&D Systems, Minneapolis, MN). Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) activities were evaluated using an immunoactivity assay using commercial kits.
Statistical Analyses
Data are expressed as means Ϯ SD or medians (interquartile ranges). Kolmogorov-Smirnov test was used to analyze the normality of the distribution of the parameters measured. We assessed differences between baseline and 6-mo values using the 2 test and t test for paired data, univariate analysis for normally distributed variables and MannWhitney U test for skewed variables. Spearman correlation coefficients were used to evaluate the relationship between lipid parameters and inflammatory mediators. Statistical significance was assumed at P Ͻ 0.05.
Results
All patients from group A and 19 from group B completed the study; three were excluded from the study because they were lost in the follow-up. Patients with CKD showed a higher serum CRP (P ϭ 0.002), IL-1␤ (P ϭ 0.004), TNF-␣ (P ϭ 0.000), and IL-6 levels (P ϭ 0.001) compared with the control group (Table 1) . t-PA levels were significantly elevated in patients with CKD (P ϭ 0.000), and no differences were observed in PAI-1 levels (Table 1) . Table 2 lists baseline characteristics of the patients with CKD. There were no statistically significant differences between the two study groups at the baseline evaluation.
Comparison of average serum lipid levels at the baseline and at the 6-mo end point showed the expected variations during atorvastatin therapy in group A patients (Table 3) : A significant reduction in serum total cholesterol levels (P Ͻ 0.001) and serum LDL cholesterol levels (P Ͻ 0.001). Conversely, the same procedures showed no significant variations in lipid levels in group B patients (Table 3) .
Serum CRP levels decreased significantly (P ϭ 0.015) in group A. However, they remained stable in group B (Table 4 ). In addition, changes in CRP and serum cholesterol during the study were not correlated, suggesting that the atorvastatininduced cholesterol and CPR reduction are independent from one another. In addition IL-1␤ and TNF-␣ showed significant reductions in group A (P ϭ 0.001 and P ϭ 0.046, respectively) and remained unchanged in group B. Reduction of IL-6 was not statistically significant in group A. Serum fibrinogen, t-PA, and PAI-1 were not modified by atorvastatin therapy (Table 4) . Renal function was not changed during the 6-mo period, and no significant differences were observed in these parameters between group A and group B (Table 3) .
Discussion
Pleiotropic effects of statins have important clinical implications, independent of their lipid-lowering effects (8 -13) . Alterations in inflammatory responses, plaque stabilization, and improved endothelial function are thought to be partially responsible for the reduction in cardiovascular morbidity and mortality (14) . Patients with CKD, even those in the early stages of the disorder, are at increased risk for CVD, and recent reviews suggested that oxidant stress and inflammation may be a Data are average Ϯ SD or median (25th to 75th percentiles). CKD, chronic kidney disease; CRP, C-reactive protein; t-PA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor-1. the primary mediators or the "missing link" that explains the burden of CVD in patients with CKD (15). Although statins reduced the incidence of cardiovascular events in patients with type 2 diabetes (16), these findings were not confirmed in patients who were on hemodialysis in a recently published large, prospective study (17) .
A few recent studies described the impact of statins on serum CRP levels in patients who were on long-term HD therapy. Ichihara et al. (18) showed that fluvastatin (20 mg/d orally for 24 wk) significantly reduced serum CRP levels in these patients. Similar results were obtained by Chang et al. (19) by testing simvastatin (20 mg/d orally for 8 wk) and by Vernagione et al. (20) (atorvastatin 10 mg/d orally for 6 mo).
Our study describes the impact of atorvastatin on inflammatory parameters in nondialysis patients with CKD. Recently, Panichi et al. (17) described that simvastatin in commonly used dosages has an in vitro and in vivo anti-inflammatory effect in patients with CKD. Our study confirms the findings of other authors (21, 22) , showing that patients with CKD have higher levels of inflammatory markers, such as CRP, IL-1␤, IL-6, and TNF-␣, than general population. As described in patients who had ESRD and were on HD therapy, statin treatment in group A patients significantly reduced inflammatory parameters (CRP, IL-1␤, and TNF-␣) levels. Moreover, the absence of correlation between reduction in serum CRP and serum total cholesterol and serum LDL cholesterol levels that were obtained in patients in group A indicates that the anti-inflammatory effects of atorvastatin likely are independent of its lipidlowering action.
Our study shows that CRP and IL-6 are significantly associated (r 2 ϭ 0.519, P Ͻ 0001). However, there is no significant reduction in plasma IL-6 after statin treatment. IL-6 is an important regulator of CRP expression in the liver but not the only one (21) . Therefore, it is probable that other cytokines (IL-1␤ and TNF-␣) may be involved in CRP regulation. An alternative explanation for the discordant findings in CRP and IL-6 concentrations may be that the later has a greater diurnal variability and shorter half-life (2 to 4 h) than CRP (24 h). Impaired fibrinolysis has been acknowledged as a risk factor for cardiovascular ischemic complications. It has been speculated that the development of atherothrombotic events in hemodialysis patients is due, at least in part, to an impaired fibrinolysis (23) . Limited data have been published about the fibrinolytic system in patients who have CKD and do not require chronic HD. Lottermoser et al. (22) showed that patients who were on hemodialysis therapy had a fibrinolysis system disturbed, with t-PA concentrations markedly decreased and PAI-1 antigen concentrations unmodified compared with normal renal function group. However, no differences were observed in patients with impaired renal function (creatinine 1.3 to 6.5 mg/dl) in this study. Unexpected, our results showed that patients with moderate CKD have elevated t-PA concentrations compared with normal renal function, whereas PAI-1 antigen remained unchanged with respect to the normal renal function group. Although no direct evidence is offered in this work, it might be hypothesized that elevated t-PA levels could be a consequence of an enhanced procoagulant state in patients with CKD, which has been reported in patients with CKD, probably as a consequence of uremia.
Finally, several experimental and clinical studies have shown that statins produced favorable effects on thrombotic parameters (24) . Statins diminish procoagulant activity, which is observed at various stages of the coagulation cascade (25) . In some studies that were performed in patients who were on peritoneal dialysis, statins reduced fibrinogen levels and altered the levels and activities of t-PA and PAI-1 (26, 27) . To our knowledge, there are no available data in azotemic patients before the development of ESRD about the effect of statins on fibrinolysis. In our study, 6-mo atorvastatin treatment did not modify fibrinolysis parameters: Serum fibrinogen, t-PA, and PAI-1 levels.
Conclusion
Treatment with atorvastatin (20 mg/d) for 6 mo in nondialysis patients with CKD induced, in addition to its lipid-lowering effect, a significant decrease in inflammatory parameters. Such evidence, similar to that observed in hemodialysis patients, could suggest a new therapeutic use of statins in the prevention of cardiovascular damage in patients with CKD.
